Found 141 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
Please refer to Protocol Section1.3 (Core Objectives and Endpoints). Please refer to Protocol Section1.3 (Core Objectives and Endpoints). Please refer to Protocol Section1.3 (Core Objectives and Endpoints).
mNET is commonly treated with TACE or TACE. mNET cells can survive TACE or TARE ischemic conditions. In this study, we will biopsy mNETs being treated with TACE or TARE prior to treatment, after treatment, and again at recurrence to characterize the metabolic, immunologic, and genetic profile of the cells …
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161. We would like to rely on WCG IRB as the IRB of record for this study.
This phase 3 trial studies how well active surveillance help doctors to monitor subjects with low-risk germ cell tumors for recurrence after their tumor is removed. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells. The trial studies whether carboplatin or cisplatin is the …
An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel inhibitors of active, GTP-bound RAS (RAS[ON]), in combination with other anticancer therapies in patients with gastrointestinal solid tumors.
Please refer to Protocol Section 4.0 (Objectives and endpoints). Please refer to Protocol Section 4.0 (Objectives and endpoints). Please refer to Protocol Section 4.0 (Objectives and endpoints).
The primary hypothesis of this study is that the combination of tocilizumab, atezolizumab , and FSRT will lead to a robust anti-tumor immune response in GBM. This hypothesis is based on strong preclinical data, which has demonstrated (1) critical roles for IL-6 in GBM immune evasion, (2) that targeting IL-6 …
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: 1) to identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and 2) to assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy.
